Y Intercept Hong Kong Ltd Lowers Stock Position in Vera Therapeutics, Inc. $VERA

Y Intercept Hong Kong Ltd trimmed its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) by 60.4% during the first quarter, HoldingsChannel.com reports. The fund owned 11,670 shares of the company’s stock after selling 17,772 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Vera Therapeutics were worth $469,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also modified their holdings of the business. GAMMA Investing LLC raised its position in Vera Therapeutics by 50.5% in the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after purchasing an additional 236 shares during the last quarter. Los Angeles Capital Management LLC purchased a new position in Vera Therapeutics during the 4th quarter worth $46,000. Quantbot Technologies LP purchased a new position in Vera Therapeutics during the 2nd quarter worth $51,000. Aster Capital Management DIFC Ltd acquired a new position in Vera Therapeutics in the fourth quarter valued at $71,000. Finally, Tower Research Capital LLC TRC increased its stake in Vera Therapeutics by 192.9% in the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock valued at $99,000 after purchasing an additional 2,757 shares during the period. 99.21% of the stock is owned by institutional investors and hedge funds.

Vera Therapeutics Stock Performance

Shares of VERA stock opened at $43.13 on Wednesday. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.15. The stock has a 50 day simple moving average of $36.92 and a 200-day simple moving average of $40.84. The company has a market cap of $3.10 billion, a price-to-earnings ratio of -7.79 and a beta of 0.92. Vera Therapeutics, Inc. has a 12-month low of $19.07 and a 12-month high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same quarter in the previous year, the firm posted ($0.81) earnings per share. On average, equities analysts forecast that Vera Therapeutics, Inc. will post -6.37 EPS for the current year.

Insider Transactions at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 46,250 shares of the firm’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $42.30, for a total value of $1,956,375.00. Following the completion of the sale, the chief executive officer owned 151,994 shares of the company’s stock, valued at approximately $6,429,346.20. This trade represents a 23.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 83,250 shares of company stock valued at $3,337,770 in the last three months. Corporate insiders own 15.90% of the company’s stock.

Analyst Upgrades and Downgrades

VERA has been the subject of several recent research reports. HC Wainwright increased their target price on shares of Vera Therapeutics from $110.00 to $125.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. William Blair restated an “outperform” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Evercore set a $91.00 price target on Vera Therapeutics in a research report on Friday, May 15th. Jefferies Financial Group reaffirmed a “buy” rating and set a $60.00 price objective on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Finally, Needham & Company LLC set a $125.00 price objective on Vera Therapeutics in a research report on Wednesday, July 8th. Eleven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Vera Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $84.58.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.